Incyte's revenues continues to grow, with full-year 2024 revenues reaching $4.2 billion, driven by JAKAFI and OPZELURA. Click ...
Key Takeaways Incyte shares sank Monday after the drugmaker released the latest data from a clinical trial.The drug, ...
Investor's Business Daily on MSN3d
Incyte Plummets 13% As Skin Disease Drug Looks 'Viable, But Not Competitive'Incyte's skin disease treatment looks "viable, but not competitive with biologics," an analyst said Monday as Incyte stock crashed.
As previously reported, Guggenheim downgraded Incyte (INCY) to Neutral from Buy and removed the firm’s previous $92 price target after the ...
Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients with Hidradenitis ...
US biotech Incyte (Nasdaq: INCY) has reported positive results from two Phase III trials of povorcitinib, an oral JAK1 ...
Incyte has delivered a pair of pivotal wins for an oral JAK inhibitor in an inflammatory skin condition. But with the placebo ...
The Wilmington, Del., biopharmaceutical company said the study data support planned worldwide regulatory submissions for povorcitinib for the treatment of hidradenitis suppurativa, which can lead to ...
Truist lowered the firm’s price target on Incyte (INCY) to $72 from $74 and keeps a Hold rating on the shares. Following the ...
Newly released data from the phase 3 STOP-HS clinical trial program reveal positive results in hidradenitis suppurativa from ...
Incyte (INCY) announced topline results from its Phase 3 STOP-HS clinical trial program evaluating the safety and efficacy of povorcitinib, an ...
Incyte's Phase 3 STOP-HS trials showed povorcitinib met primary endpoints, with up to 42.3% of patients achieving HiSCR50 at Week 12. Povorcitinib demonstrated greater efficacy in biologic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback